Purpose-to evaluate the toxic effects and antitumour activity of a multidrug regimen with cisplatin, epirubicin and paclitaxel (CEP) as initial therapy in patients with uterine adenocarcinoma.
Introduction
The term 'uterine adenocarcinoma'embraces two different pathological entities, endometrial cancer of the corpus, which is the most common invasive malignancy of the female genital tract in developed countries [1] , and adenocarcinoma of the uterine cervix; the latter comprises 5%-15% of cervical cancers [2] and there is a virtually general consensus that adenocarcinoma carries a worse prognosis than its squamous counterpart, at least in locally advanced disease.
Multidrug regimens with cisplatin and doxorubicin have shown remarkable antitumour activity in tumours whose glandular component, like those of the cervix and endometrium, originates in the Mullerian tissue [3, 4] . An overall response rate of 36% has been reported with single-agent paclitaxel (P) in patients with endometrial carcinoma with tumour recurrence after local therapy [5] , while an overall response rate of 37% has been reported with P alone in patients with endometrial adenocarcinoma failing cisplatin and anthracyclines [6] . These results prompted the evaluation of P in combination with cisplatin (C) and epirubicin (E) as initial therapy for women with locally advanced, recurrent or metastatic uterine adenocarcinoma.
Patients and methods
From January 1996 to January 1997, 49 consecutive patients with uterine adenocarcinoma, originating from either the endometrium (30 patients) or the endocervical epithelium (19 patients), with a mean age of 53 years (range 31-75 years), entered the study. All patients had bidimensionally-measurable disease, outside the irradiation field in cases of previous adjuvant pelvic radiation.
Pretreatment evaluation, which had to be performed within the two weeks preceding the start of treatment, included determination of complete hematology and chemistry profiles, pelvic examination, tumour imaging by MRI or CT scan, and echocardiogram with calculation of the left ventricular ejection fraction (LVEF).
Eligibility criteria included age < 75 years, a performance status (PS) < 1 according to WHO, a neutrophil count (ANQ of > 2.0 x 10 clearance > 60 ml/min) and cardiac (LVEF > 50%) functions, written informed consent.
Chemotherapy was administered on an outpatient basis according to the following schedule: E (70 mg/m 2 ) was given diluted in 250 ml of normal saline solution as a 15-min infusion, followed by P (175 mg/m 2 ) as a three-hour infusion, and then by C (50 mg/m 2 ) diluted in 100 ml of normal saline solution at the infusion rate of 1 mg/min. 135 mg/m 2 of P was given to the first four patients who entered the study to assess the tolerability of the combination, as well as to patients with prior pelvic irradiation. One hour before the administration of P, patients were premedicated with hydrocortisone (250 mg i.v.), followed by chlorphenamine (10 mg i.m.) and cimetidine (300 mg i.v.) 30 minutes before the P was started. A two-hour prehydration with 500 ml of normal saline solution and 500 ml of 5% dextrose, both added with 10 mEq/1 potassium chloride and 10 mEq/1 MgSCj, preceded the C administration. Post-hydration consisted of 1000 ml of normal saline solution added with 20 mEq/1 of both potassium chloride and MgSO 4 , infused over four hours. Antiemetic prophylaxis with 5HT3 antagonists was routinely given.
Complete blood cell counts were performed at least weekly, and more often in case of neutropenia of grade > 2, while chemistries, including creatinine clearance, were checked before each cycle. Treatment was repeated every three weeks if ANC 5*1.5 x lO 3 /^ and Pt count was > 100,000 x lO^ul; otherwise it was delayed by one week. Reduction of the drug doses was not planned. Recombinant human G-CSF (5 ug/kg/d s.c.) was administered at the discretion of the physician, until a WBC of > 20,000 x 10 3 / ul was reached Pelvic examination was performed before each cycle. In the absence of clinical evidence of tumour progression, tumour response by diagnostic imaging (X-rays, MRI, CT scan) was first assessed after three cycles by the method used at baseline. Response and toxicity were defined according to the WHO criteria [7] . Patients were evaluable for response if they had received at least one cycle and subsequently survived for at least three weeks. Patients were evaluable for hematological toxicity if weekly blood counts were available and for non-hematological toxicity if they were evaluable at least one week after the treatment.
In instances of response after three cycles, which required to be documented by a repeat measurement after four weeks, patients with stages IB/II locally advanced cervical cancer or stage II endometrial adenocarcinoma underwent surgery, while those with advanced or recurrent disease continued treatment up to a total of six cycles, when tumour evaluation was repeated. Responders underwent surgery, while patients with metastatic disease were given two additional courses. Patients in complete or partial response after eight cycles received no additional chemotherapy.
The criteria for evaluation of pathological response were: complete response: no evidence of tumor on the histopathologic specimen; optimal partial response (OP): microscopic histopathological residual tumor; suboptimal partial response: macroscopic residual tumor or positive lymph node(s) on pathology report; stable disease: no evidence of > 50% reduction on the surgical specimen; progressive disease: evidence of increasing disease. Subsequent radiotherapy to the site of persisting disease was left to the discretion of the investigator.
Follow-up procedures with pelvic examination and vaginal cytology were performed one month after the end of treatment and every two months thereafter. In patients with complete response, abdominopelvic US or CTscan were performed every three months.
The duration of partial and complete responses was calculated from the start of treatment until the documentation of tumour progression. Survival was defined as the time interval from entry into the study to death, or to the date of the last contact. IIIB in one and IIIC in five cases) and seven had metastatic disease (lung in five and distant nodes in two cases). Ten patients, six of whom had previously been irradiated, presented recurrence in either the retroperitoneal nodes (six cases) or the pelvis (four cases). Previous surgery had been performed in all recurring patients, two with stage IIIC and one with stage IVB. A median of six CEP cycles were administered (range 1-8).
Results
Of 19 patients with cervical adenocarcinoma, four had stage IB] (size ^ 4 cm but with poorly differentiated (G3) tumour, 10 stage IB 2 (size > 4 cm and G 2 or G 3 in seven and one case), two stage IV, one stage IIIB, and two had recurrences in the pelvis. A median of three CEP cycles were administered (range 2-7).
The clinical and pathological response in patients with endometrial carcinoma is reported in Table 2 . The overall clinical response rate in 30 evaluable patients was 73% (95% CI, range 54%-88%) with 23% of complete response; the overall response rate in patients with metastatic disease was 86% with a median duration of seven months (range 2-12+). In 13 patients surgery was not performed because of metastatic disease in six cases, lack of clinical response in two, tumour regrowth while on treatment after an initial response in four, and previous surgery in one. The pathological response rate in 23 patients with locally advanced or recurrent disease was 35% (95% CI, range 16%-57%) with 13% of the patients without residual tumour. Radiotherapy to the retroperitoneum was administered to three patients whose surgical specimens showed residual nodal disease.
In 19 evaluable patients with adenocarcinoma of the cervix the clinical response rate was 53% (95% CI, range 30%-76%) with 16% of patients without residual tumour (Table 3) ; the clinical response rate to CEP given as neoadjuvant treatment to 14 patients with stage IB tumour was 64%; surgery was performed in 12 patients after a median of three cycles, with pathological partial and complete remissions in 56% and 6% of them. Of eight partial responders, two had only microscopic residual disease, three had macroscopic residual disease and three had positive lymph nodes. The patients who were pathologically evaluated as having no change received a different chemotherapy, while no additional Table 2 . Antitumour activity of CEP in endometrial adenocarcinoma. (4) I1IB (1) IIIC (5) Recurrence Retroperitoneum (6) Pelvis (4) IVB (7 treatment was given to responders. The median duration of response was 9+ months (range 3+-12). No responses were observed in patients with stages III and IV. Table 4 reports the toxicity observed in 39 patients (20 with endometrial and 19 with cervical adenocarcinoma) treated with P at 175 mg/m 2 and in 10 patients with endometrial carcinoma treated with P at 135 mg/m 2 . Neutropenia > grade 3 occurred in 60% of patients who received P at 135 mg/m 2 and in 61% of those treated at 175 mg/m 2 . One toxic death occurred after the third cycle at 175 mg/m 2 in a patient who developed a septic shock while on neutropenia. Six patients treated at 175 Table 3 . Antitumour activity of CEP in cervical adenocarcinoma. /ul up to recovery; treatment in 34% of patients was delayed by one week because of persisting neutropenia on day 21, without dose modification in subsequent cycles. Mild peripheral neuropathy and mucositis occurred in 46% and 23% of patients treated at 175 mg/m 2 . One 75-yearold patient treated at 135 mg/m 2 of P for a lymph node recurrence of endometrial carcinoma, pretreated with intracavitary radiotherapy, and normal baseline LVEF, developed an acute congestive heart failure after the third cycle, with a > 20% decrease of LVEF.
Discussion
Although preliminary, the results of this study confirm initial reports of a significant antitumour activity of paclitaxel in endometrial carcinoma. Notwithstanding the brief follow-up period, the small size of this series and the different characteristics of the patients evaluated, it appears that the use of paclitaxel in combination with cisplatin and epirubicin has resulted in an overall response rate of 73%, with a complete response rate higher by 23% than the 46% reported with cisplatin and doxorubicin [8] . In the present study, post-treatment surgery has been performed after a maximum of six cycles in patients with advanced or recurrent disease amenable to surgical debulking, with the report of 35% of overall response and 13% of complete responses. These results, as well as the good tolerability of CEP, suggest that this regimen should be prospectively compared to standard treatment with cisplatin and anthracyclines in patients with advanced or metastatic endometrial cancer [9] and that CEP could be included in a combined approach of neoadjuvant chemotherapy followed by surgery, with /without subsequent radiotherapy, in the treatment of locally advanced high-risk patients. Peripheral neuropathy, which occurred in 46% of patients, was of mild degree only, even in patients who received eight cycles of treatment. This reduced neurotoxicity might be ascribed to the low-dose of C used in the CEP regimen since 78% of mild to moderate neuro-toxicity was reported after five to six courses of P, given at the same dose of 175 mg/m 2 , and C at 75 mg/m 2 [10] . Still to be defined with CEP are the optimal duration of treatment, timing of surgery and need of additional radio-or chemotherapy.
When given as neoadjuvant therapy in locally advanced cervical adenocarcinoma, three cycles of CEP resulted in overall clinical and pathological response rates of 64% and 62%, respectively, with 6% of patients with complete response and 12% with microscopic residual tumour. These results suggest that paclitaxel is active also in this tumour type. The results of the present study compare favourably to those reported by our group with weekly cisplatin and epirubicin, whereby an overall pathological response rate of 47% without complete response and with 19% microscopic partial response was reported [11] . In addition, the regimen was poorly tolerated, treatment had to be discontinued in 20% of cases and subsequent radiotherapy to the pelvis or retroperitoneum could not be completed.
This is the first report on the clinical efficacy of paclitaxel in cervical adenocarcinoma; these encouraging results, however, need to be confirmed in a controlled clinical trial, with the aim of defining the optimal neoadjuvant therapy and with a pathological evaluation of response. The role and the choice of an additional postsurgical treatment according to pathological risk factors should also be defined in future studies.
